The global wound care biologics market was valued at USD 1,848.7 million in 2020, which will grow at a CAGR of 5.7% during the forecast period. Globally, wound care biologics industry is driven by the factors such as the mounting occurrence of the surgical wound and wound ulcer, rising healthcare expenditure, need for evidence-based treatment for chronic wounds, awareness programs for advanced wound care treatment and management, and technological advancements.

The market for wound care biologics is witnessing growth due to the increasing occurrence of the surgical wound and wound ulcers. With the expanding geriatric population, and mounting occurrence of lifestyle-associated diseases such as diabetes has resulted in the demand of wound care biologics for the management and treatment of wounds, which further decreases the length of stay in the hospital and reduces the cost involved. This offers market players immense opportunities for wound care biologics products, which will drive their revenue growth.

On the basis of product, the global wound care biologics market is categorized into growth factors, skin substitutes, cell-based, collagen-based, enzyme-based, and others. Of all, skin substitutes account for the largest share in the market. The global skin substitutes market is also anticipated to witness significant growth during the forecast period.

Download Free Sample Copy Of Research Report: https://www.vynzresearch.com/healthcare/wound-care-biologics-market/request-sample

Growth factors are further categorized into platelet-derived growth factors (PDGF), epidermal growth factors (EGF), insulin-like growth factors (IGF), transforming growth factor-beta (TGF-β), fibroblast growth factors (FGF), and others; whereas skin substitutes are further segmented into acellular animal-derived, human tissue-derived, and biosynthetic. Another category of cell-based products includes viable and non-viable segments.

Based on durability, the wound care biologics market is segmented into permanent and temporary biologics. The demand for temporary biologics has witnessed considerable growth over the last few years due to the increasing burn incidences and their lower cost compared to permanent biologics.

Based on application, the wound care biologics market is segmented into chronic and acute. Among the two categories, chronic would care biologics hold the larger market share due to the growing geriatric population and increasing incidence of pressure ulcers, diabetic foot ulcer and other ulcers.

Based on end-user, the wound care biologics market is segmented into hospitals and specialty wound care clinics, home healthcare and other end users. The hospital and specialty wound clinics are estimated to account the largest share in the wound care market due to increasing in hospitals and clinics, due to improving healthcare infrastructure in developing countries, increasing number of chronic wound cases and increasing incidence of diabetes.

Geographically, North America has accounted for the largest share in wound care biologics market, globally and is predicted to grow significantly during the forecast period. The growth of this market is attributed towards the existence of a large number of industry players, growing research activities, the highest healthcare expenditure globally, and increasing incidence of burn cases and prevalence of diabetes.

For instance, according to Centers for Disease Control and Prevention (CDC), in 2015 approximately 23.1 million people in the U.S. had diabetes. Moreover, Asia-Pacific is expected to witness the fastest growth during the forecast period as the region comprises of largest population and the awareness for wound management is increasing rapidly among them. In addition, government support for wound management is also creating a positive impact on the wound care biologics market growth in the region.

Some of the key players operating in the global wound care biologics market are Integra LifeSciences Corporation, MiMedx Group Inc., Wright Medical Group N.V., Osiris Therapeutics Inc., Vericel Corporation, Kerecis Limited, Anika Therapeutics Inc., Acell Inc., Skye Biologics Inc., Solsys Medical, Marine Polymer Technologies Inc., Kerecis Limited, Smith & Nephew plc, and Mölnlycke Health Care AB.

Source: VynZ Research